CALLTEVA.TA
Teva: the pipeline is worth more than the balance sheet discount
The leverage that justified the discount has come down four turns while the pipeline improved. Neither has been re-rated.
The economics turn on exclusivity. A launch with limited competition earns close to monopoly economics for its exclusivity window, and the window length is known in advance.
The pipeline evidence is regulatory rather than commercial. Three filings have accepted review dates inside eighteen months and two face no filed competitor.
The position: long on Teva, entry locked at publication and the exit dated rather than open-ended. The target is stated in the call block above and the horizon with it. Sized to the catalyst rather than to conviction, with the invalidation written into the kill-switch card instead of left implicit.
The risk is a manufacturing failure or a regulatory hold on a new line, which converts a capacity story into a multi-quarter delay with no offset.
Discussion · 4
Yael BrennerAUG 3
Been on the sidelines on this one. The margin bridge is doing more work here than is acknowledged. How are you thinking about the timing risk here?
9
Dana KatzAUG 2
This changed my mind. The destocking signature is textbook and nobody is naming it. Curious whether you would still size it the same at a higher entry.
26
Sofia LindqvistAuthorJUL 31
Fair challenge. Invalidation is a close below the lock price on volume, and I should have written that into the card rather than leaving it implicit. (919)
22
Marco BianchiAUG 2
I came in sceptical. The mix argument is the part I had not considered properly. Where does this break if rates back up another 50bp?
26